biotech M&A
Merck’s Strategic Gambit: Why a Potential Deal for Cidara’s Flu Drug Could Reshape Preventative Medicine and Your Portfolio
Merck’s potential acquisition of Cidara Therapeutics signals a major shift in flu prevention, impacting healthcare, finance, and the broader economy.
Pfizer’s $10 Billion Gambit: Winning the War for Metsera and the Future of Weight Loss
Pfizer outmaneuvered rival Novo Nordisk in a $10bn bidding war for weight-loss startup Metsera, a strategic move to combat its looming patent cliff.